(Q43228479)

16 November 2017

title

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease (English)

1 reference

16 November 2017

1 reference

14

1 reference

16 November 2017

D Hoda

1

1 reference

16 November 2017

J Pidala

2

1 reference

16 November 2017

N Salgado-Vila

3

1 reference

16 November 2017

J Kim

4

1 reference

16 November 2017

J Perkins

5

1 reference

16 November 2017

R Bookout

6

1 reference

16 November 2017

T Field

7

1 reference

16 November 2017

L Perez

8

1 reference

16 November 2017

E Ayala

9

1 reference

16 November 2017

J L Ochoa-Bayona

10

1 reference

16 November 2017

J Raychaudhuri

11

1 reference

16 November 2017

M Alsina

12

1 reference

16 November 2017

J Greene

13

1 reference

16 November 2017

H F Fernandez

15

1 reference

16 November 2017

C Anasetti

16

1 reference

16 November 2017

M A Kharfan-Dabaja

17

1 reference

16 November 2017

language of work or name

English

0 references

publication date

7 December 2009

1 reference

Bone Marrow Transplantation

16 November 2017

published in

1 reference

16 November 2017

volume

45

1 reference

16 November 2017

issue

8

1 reference

16 November 2017

page(s)

1347-1351

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2009.343

16 November 2017

exact match

0 references

cites work

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Pentostatin in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Assessing the potential role of photopheresis in hematopoietic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

Graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.343

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2009.343

1 reference

Dimensions Publication ID

16 November 2017

1033621648

0 references

1 reference